Trials / Completed
CompletedNCT00280423
Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia
A 28 Day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 342 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to find the optimal (best) doses of GW679769 that could be given daily to promote sleep onset and maintain sleep during the night without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW679769 |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2006-01-23
- Last updated
- 2015-04-15
Locations
71 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00280423. Inclusion in this directory is not an endorsement.